Login to Your Account

On the Rebound

Stem Cell Sector Gets a Healthy Shot in the Arm

By Peter Winter
BioWorld Insight Editor

Thursday, June 7, 2012
After a relatively tough year for stem cell companies on the public markets, they finally had something to cheer about – a regulatory milestone that could pave the way for a number of future approvals of stem cell therapies currently in late-stage clinical trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription